HSK7653 10 mg

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

CompletedNCT06059326

Haisco Pharmaceutical Group Co., Ltd.Type 2 Diabetes Mellitus

Start: 2019-01-22End: 2019-11-05Updated: 2023-09-28

A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

CompletedNCT06703268

Haisco Pharmaceutical Group Co., Ltd.Type 2 Diabetes

Start: 2024-01-15End: 2024-11-20Updated: 2024-11-25

Related Papers

863-P: A Multicenter, Randomized, Open-Label, Controlled Study on Evaluating the Efficacy and Safety of Switching from Daily DPP-4 Inhibitors to Cofrogliptin in Patients with Type 2 Diabetes Mellitus in China

Diabetes2025-06-13